MHRA Drug Safety Update – October 2018

MHRA Drug Safety Update – October 2018

October 11, 2018

Date issued: 11th October 2018

A new Medicines and Healthcare products Regulatory Agency (MHRA) Drug Safety Update (Vol 12 Issue 3, October 2018) has been published and includes articles on:

  • Rivaroxaban (Xarelto▼) after transcatheter aortic valve replacement: increase in all-cause mortality, thromboembolic and bleeding events in a clinical trial.
  • Ritonavir-containing products: reports of interaction with levothyroxine leading to reduced thyroxine levels.
  • Ponatinib (Iclusig▼): reports of posterior reversible encephalopathy syndrome.
  • Transdermal fentanyl patches: life threatening and fatal opioid toxicity from accidental exposure, particularly in children.

To see the latest MHRA Drug Safety Update in full, visit the GOV.uk website.



Posted in:


More Latest News >

Ask PSNC: Flu FAQs

The team at PSNC has received a number of queries on the NHS Flu Vaccination Service 2018/19. Below are some...

Book now for our FMD webinar

PSNC will be holding a webinar about the Falsified Medicines Directive (FMD) on Tuesday 30th October at 7.00pm. On the night Alastair...